ES3064007T3 - Composition comprising choline, succinate and nicotinamide and its use in brain energy metabolism - Google Patents

Composition comprising choline, succinate and nicotinamide and its use in brain energy metabolism

Info

Publication number
ES3064007T3
ES3064007T3 ES18739590T ES18739590T ES3064007T3 ES 3064007 T3 ES3064007 T3 ES 3064007T3 ES 18739590 T ES18739590 T ES 18739590T ES 18739590 T ES18739590 T ES 18739590T ES 3064007 T3 ES3064007 T3 ES 3064007T3
Authority
ES
Spain
Prior art keywords
energy metabolism
nicotinamide
succinate
choline
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18739590T
Other languages
English (en)
Inventor
Larisa Andreeva
Igor Anatolievich Pomytkin
Galina Nonina Skladtchikova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitocholine Ltd
Original Assignee
Mitocholine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1710316.9A external-priority patent/GB201710316D0/en
Priority claimed from GBGB1715214.1A external-priority patent/GB201715214D0/en
Priority claimed from GBGB1800244.4A external-priority patent/GB201800244D0/en
Priority claimed from GBGB1807733.9A external-priority patent/GB201807733D0/en
Application filed by Mitocholine Ltd filed Critical Mitocholine Ltd
Application granted granted Critical
Publication of ES3064007T3 publication Critical patent/ES3064007T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones, en particular composiciones dietéticas, que comprenden una combinación de catión colina y anión succinato (2-) y nicotinamida, y al uso de estas composiciones para mantener y mejorar el metabolismo energético cerebral en un ser humano, y para prevenir y tratar síntomas y afecciones fisiológicas asociadas con un metabolismo energético cerebral desequilibrado, dañado o ralentizado en un sujeto humano. (Traducción automática con Google Translate, sin valor legal)
ES18739590T 2017-06-28 2018-06-27 Composition comprising choline, succinate and nicotinamide and its use in brain energy metabolism Active ES3064007T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1710316.9A GB201710316D0 (en) 2017-06-28 2017-06-28 Dietary composition of nicotinamide riboside, choline and succinic acid or salts thereof
GBGB1715214.1A GB201715214D0 (en) 2017-09-20 2017-09-20 A dietary composition comprising choline succinate salt (2:1) and nicotinamide, and nicotinamide riboside/or nicotinamide derivative
GBGB1800244.4A GB201800244D0 (en) 2018-01-08 2018-01-08 Nutritional composiion
GBGB1807733.9A GB201807733D0 (en) 2018-05-12 2018-05-12 GB04 nutritional composition nicotinamide+
PCT/GB2018/051797 WO2019002858A1 (en) 2017-06-28 2018-06-27 COMPOSITION

Publications (1)

Publication Number Publication Date
ES3064007T3 true ES3064007T3 (en) 2026-04-22

Family

ID=62873492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18739590T Active ES3064007T3 (en) 2017-06-28 2018-06-27 Composition comprising choline, succinate and nicotinamide and its use in brain energy metabolism

Country Status (9)

Country Link
US (3) US11571415B2 (es)
EP (1) EP3644959B1 (es)
JP (2) JP7367978B2 (es)
KR (1) KR102702576B1 (es)
CN (1) CN110869001B (es)
AU (1) AU2018293426B2 (es)
CA (1) CA3067959A1 (es)
ES (1) ES3064007T3 (es)
WO (1) WO2019002858A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869001B (zh) * 2017-06-28 2024-05-24 米拓克兰有限公司 组合物
US12569477B2 (en) * 2017-06-28 2026-03-10 Mitocholine Ltd Compositions for synergistically enhancing mitochondrial function
CN109939120B (zh) 2019-03-01 2020-01-31 北京慧宝源生物技术股份有限公司 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
GB202107957D0 (en) 2021-06-03 2021-07-21 Mitocholine Ltd Nutritional compositions for skeletal muscle
GB202112170D0 (en) * 2021-08-25 2021-10-06 Mitocholine Ltd Nutritional compositions
CN114344209B (zh) * 2021-12-23 2023-10-20 健合香港有限公司 一种延缓衰老的组合物和制备方法及其用途
KR20240032679A (ko) * 2022-09-02 2024-03-12 주식회사 렉스팜텍 신규 벤포티아민 콜린염
EP4705272A1 (en) 2023-05-05 2026-03-11 Mitocholine Ltd Method of synthesis
WO2025120626A2 (en) 2025-04-14 2025-06-12 Mitocholine Ltd Synthetic method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579423A (en) * 1968-12-13 1971-05-18 Flow Lab Preparation of tissue culture media
EP1654244A1 (en) 2003-08-11 2006-05-10 Wyeth 3-aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
RU2281766C1 (ru) * 2005-03-04 2006-08-20 Игорь Анатольевич Помыткин Способ улучшения когнитивной функции
US8367121B2 (en) * 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
US7989007B2 (en) * 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009022933A1 (en) 2007-08-02 2009-02-19 Buddha Biopharma Oy Ltd Pharmaceutical compositions for intranasal administration comprising choline salts of succinic acid
KR101360569B1 (ko) 2008-11-26 2014-02-10 이고르 아나토리에비치 포밋트킨 우울증, 불안증, 정신분열증, 수면장애 및 간질의 치료를 위한 숙신산의 콜린염
EP2654779B1 (en) * 2010-12-23 2018-02-28 Ludwig Institute for Cancer Research, Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
JP2017526638A (ja) * 2014-06-30 2017-09-14 ミトコンドリアル サブストレート インベンション リミテッドＭｉｔｏｃｈｏｎｄｒｉａｌ Ｓｕｂｓｔｒａｔｅ Ｉｎｖｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ 認知機能向上のための栄養素溶液
CN110869001B (zh) * 2017-06-28 2024-05-24 米拓克兰有限公司 组合物

Also Published As

Publication number Publication date
KR102702576B1 (ko) 2024-09-05
US20240066019A1 (en) 2024-02-29
US20200171019A1 (en) 2020-06-04
US11571415B2 (en) 2023-02-07
AU2018293426A1 (en) 2020-01-16
US12285423B2 (en) 2025-04-29
JP2020525439A (ja) 2020-08-27
WO2019002858A1 (en) 2019-01-03
EP3644959C0 (en) 2025-12-10
CA3067959A1 (en) 2019-01-03
CN110869001B (zh) 2024-05-24
KR20200018563A (ko) 2020-02-19
CN110869001A (zh) 2020-03-06
JP7367978B2 (ja) 2023-10-24
US20230087789A1 (en) 2023-03-23
EP3644959B1 (en) 2025-12-10
EP3644959A1 (en) 2020-05-06
AU2018293426B2 (en) 2024-05-02
US11826362B2 (en) 2023-11-28
JP2023071851A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2017005626A2 (es) Una composición que comprende bacteroides thetaiotaomicron
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112018074454A2 (pt) composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal
GT201500293A (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
BR112016027867A2 (pt) composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, de carboidrato, para reduzir o índice glicêmico e para inibir a elevação do nível de açúcar, composição cosmética, uso da composição de fibra e composição
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
PH12015502351A1 (en) Herbal compositions for treating pain and skin disorders